Pub Date : 2024-09-20DOI: 10.1097/CEJ.0000000000000912
Tao Hu, Li Li, Jinfeng Cui, Xiaoyu Song, He Zhu, Zhi Wei Hou, Shuanghu Yuan
To investigate the effects of antibiotic exposure on the prognosis of patients with advanced metastatic non-small cell lung cancer (m-NSCLC) who received immune checkpoint inhibitors (ICIs). This study retrospectively included 199 patients diagnosed with m-NSCLC in Shandong Cancer Hospital and Institute from December 2017 to October 2021, all patients received ICIs for the first time. The basic clinical characteristics of patients before the first treatment of ICIs, whether antibiotics were used during treatment, progression-free survival (PFS), and overall survival (OS) were collected. The survival among different groups was compared by the Kaplan-Meier method. The median follow-up time of m-NSCLC patients was 33.79 months, mPFS was 11.67 months, and mOS was 21.55 months. Univariate analysis showed that antibiotic use, radiotherapy, and targeted drug resistance influenced PFS and OS (P < 0.05). Multivariate analysis showed that antibiotic use, radiotherapy, and targeted resistance remained independent factors of PFS, and targeted resistance was an independent factor of OS (P < 0.05). Subgroup analysis found that antibiotic use within 30 days before and after immunotherapy could decrease the PFS and OS (P < 0.05). Kaplan-Meier analysis showed that patients without radiotherapy had shorter PFS (mPFS, 12.89 vs. 8.13 months; P = 0.0258) and OS (mOS, 26.94 vs. 16.43 months; P = 0.0465). The mPFS (16.17 vs. 9.19 months; P = 0.0151) and mOS (27.27 vs. 18.65 months; P = 0.0437) of patients in the antibiotic group were shorter. Patients in the targeted drug-resistant group had shorter PFS (mPFS, 40.66 vs. 7.77 months, P < 0.001) and OS (mOS, 41.98 vs. 16.89 months, P < 0.001) compared with patients who did not receive targeted treatment. Antibiotics and radiation therapy are associated with the prognosis of m-NSCLC who are newly treated with ICIs. Effectively reducing antibiotic use in 1 month before and after ICIs treatment may help improve the immunotherapy efficacy of patients with m-NSCLC.
{"title":"Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell lung cancer.","authors":"Tao Hu, Li Li, Jinfeng Cui, Xiaoyu Song, He Zhu, Zhi Wei Hou, Shuanghu Yuan","doi":"10.1097/CEJ.0000000000000912","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000912","url":null,"abstract":"<p><p>To investigate the effects of antibiotic exposure on the prognosis of patients with advanced metastatic non-small cell lung cancer (m-NSCLC) who received immune checkpoint inhibitors (ICIs). This study retrospectively included 199 patients diagnosed with m-NSCLC in Shandong Cancer Hospital and Institute from December 2017 to October 2021, all patients received ICIs for the first time. The basic clinical characteristics of patients before the first treatment of ICIs, whether antibiotics were used during treatment, progression-free survival (PFS), and overall survival (OS) were collected. The survival among different groups was compared by the Kaplan-Meier method. The median follow-up time of m-NSCLC patients was 33.79 months, mPFS was 11.67 months, and mOS was 21.55 months. Univariate analysis showed that antibiotic use, radiotherapy, and targeted drug resistance influenced PFS and OS (P < 0.05). Multivariate analysis showed that antibiotic use, radiotherapy, and targeted resistance remained independent factors of PFS, and targeted resistance was an independent factor of OS (P < 0.05). Subgroup analysis found that antibiotic use within 30 days before and after immunotherapy could decrease the PFS and OS (P < 0.05). Kaplan-Meier analysis showed that patients without radiotherapy had shorter PFS (mPFS, 12.89 vs. 8.13 months; P = 0.0258) and OS (mOS, 26.94 vs. 16.43 months; P = 0.0465). The mPFS (16.17 vs. 9.19 months; P = 0.0151) and mOS (27.27 vs. 18.65 months; P = 0.0437) of patients in the antibiotic group were shorter. Patients in the targeted drug-resistant group had shorter PFS (mPFS, 40.66 vs. 7.77 months, P < 0.001) and OS (mOS, 41.98 vs. 16.89 months, P < 0.001) compared with patients who did not receive targeted treatment. Antibiotics and radiation therapy are associated with the prognosis of m-NSCLC who are newly treated with ICIs. Effectively reducing antibiotic use in 1 month before and after ICIs treatment may help improve the immunotherapy efficacy of patients with m-NSCLC.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16DOI: 10.1097/CEJ.0000000000000924
Wei Zhao, Mingxiang Zhang, Bohui Zhu, Yueyin Pan, Yiyuan Sun
Background: We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of neoadjuvant chemotherapy in HER2-low breast cancer patients.
Methods: The study endpoint was pathological complete remission (PCR). Blood specimens and fresh cancer tissue samples were collected before neoadjuvant chemotherapy for whole-exon sequencing (WES) and RNA sequencing (RNA-seq), and patients were divided into a human epidermal growth factor receptor 2 (HER2)-low group and a HER2-0 group according to their HER2 expression status via bioinformatics analysis.
Results: A total of 409 HER2-negative breast cancer patients were included in the analysis, and HER2 status (HER2-0 vs. HER2-low) was significantly different between hormone receptor status, the Ki-67 index, and the PCR rate. A total of 18 patients who underwent WES and RNA testing were included, and the WES results suggested that the HER2-low group had a significantly higher rate of PIK3CA mutations and a greater frequency of PI3K pathway variants than the other groups and the HER2-low group had a greater number of concomitant mutations and reached statistical significance (P = 0.03). In terms of expression profiles, HER2-low and HER2-0 patients had different expression profiles. Overall, suggesting that the low PCR rate in the HER2-low group may also be related to chemoresistance.
Conclusion: Our investigation highlights the possibility that HER2-low breast cancer may indicate a unique clinical and biological phenomenon.
背景:我们旨在探讨人表皮生长因子受体2 (HER2)蛋白在HER2阴性乳腺癌中不同程度表达的临床及分子特征,以及影响HER2低水平乳腺癌患者新辅助化疗疗效的相关因素。方法:以病理完全缓解(PCR)为研究终点。在新辅助化疗前采集血液标本和新鲜肿瘤组织标本,进行全外显子测序(WES)和RNA测序(RNA-seq),并根据HER2表达情况进行生物信息学分析,将患者分为人表皮生长因子受体2 (HER2)低表达组和HER2-0组。结果:共纳入409例HER2阴性乳腺癌患者,HER2状态(HER2-0 vs HER2-low)在激素受体状态、Ki-67指数、PCR率之间存在显著差异。我们共纳入了18例进行WES和RNA检测的患者,WES结果显示HER2-low组的PIK3CA突变率和PI3K通路变异频率明显高于其他组,HER2-low组的伴随突变数量较多,差异有统计学意义(P = 0.03)。在表达谱方面,HER2-low和HER2-0患者具有不同的表达谱。总之,提示her2低组的低PCR率也可能与化疗耐药有关。结论:我们的研究强调了her2低乳腺癌可能是一种独特的临床和生物学现象。
{"title":"Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.","authors":"Wei Zhao, Mingxiang Zhang, Bohui Zhu, Yueyin Pan, Yiyuan Sun","doi":"10.1097/CEJ.0000000000000924","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000924","url":null,"abstract":"<p><strong>Background: </strong>We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of neoadjuvant chemotherapy in HER2-low breast cancer patients.</p><p><strong>Methods: </strong>The study endpoint was pathological complete remission (PCR). Blood specimens and fresh cancer tissue samples were collected before neoadjuvant chemotherapy for whole-exon sequencing (WES) and RNA sequencing (RNA-seq), and patients were divided into a human epidermal growth factor receptor 2 (HER2)-low group and a HER2-0 group according to their HER2 expression status via bioinformatics analysis.</p><p><strong>Results: </strong>A total of 409 HER2-negative breast cancer patients were included in the analysis, and HER2 status (HER2-0 vs. HER2-low) was significantly different between hormone receptor status, the Ki-67 index, and the PCR rate. A total of 18 patients who underwent WES and RNA testing were included, and the WES results suggested that the HER2-low group had a significantly higher rate of PIK3CA mutations and a greater frequency of PI3K pathway variants than the other groups and the HER2-low group had a greater number of concomitant mutations and reached statistical significance (P = 0.03). In terms of expression profiles, HER2-low and HER2-0 patients had different expression profiles. Overall, suggesting that the low PCR rate in the HER2-low group may also be related to chemoresistance.</p><p><strong>Conclusion: </strong>Our investigation highlights the possibility that HER2-low breast cancer may indicate a unique clinical and biological phenomenon.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16DOI: 10.1097/CEJ.0000000000000922
Xin Zhong, Guanyi Li, Liusheng Zhu
This meta-analysis aimed to investigate the association between dietary mineral intake and the risk of bladder cancer. Relevant studies on bladder cancer and dietary mineral intake, including sodium, calcium, iron, magnesium, phosphorus, potassium, and zinc, were systematically identified through searches in Scopus and PubMed up to July 2024. Data from 12 studies were pooled using odds ratios (OR) and 95% confidence intervals (CI) with a random-effects model. The meta-analysis of 12 studies indicated a positive association between higher dietary sodium intake and bladder cancer risk (OR = 1.62, 95% CI: 1.04-2.55), with significant heterogeneity observed. No clear linear or nonlinear dose-response relationship was found for sodium intake. However, no significant associations were found between the intake of other minerals and the risk of bladder cancer. This study suggests that a high intake of sodium is significantly associated with an increased risk of bladder cancer. Further research is needed to explore the potential mechanisms underlying this relationship.
{"title":"Dietary mineral intake and risk of bladder cancer: a systematic review and meta-analysis.","authors":"Xin Zhong, Guanyi Li, Liusheng Zhu","doi":"10.1097/CEJ.0000000000000922","DOIUrl":"https://doi.org/10.1097/CEJ.0000000000000922","url":null,"abstract":"<p><p>This meta-analysis aimed to investigate the association between dietary mineral intake and the risk of bladder cancer. Relevant studies on bladder cancer and dietary mineral intake, including sodium, calcium, iron, magnesium, phosphorus, potassium, and zinc, were systematically identified through searches in Scopus and PubMed up to July 2024. Data from 12 studies were pooled using odds ratios (OR) and 95% confidence intervals (CI) with a random-effects model. The meta-analysis of 12 studies indicated a positive association between higher dietary sodium intake and bladder cancer risk (OR = 1.62, 95% CI: 1.04-2.55), with significant heterogeneity observed. No clear linear or nonlinear dose-response relationship was found for sodium intake. However, no significant associations were found between the intake of other minerals and the risk of bladder cancer. This study suggests that a high intake of sodium is significantly associated with an increased risk of bladder cancer. Further research is needed to explore the potential mechanisms underlying this relationship.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Navy personnel and seafarers live and work 24 h per day in the shipboard environment and they are exposed to asbestos fibers released into the confined spaces aboard ships. We conducted a systematic review and meta-analysis to quantify the mesothelioma risk of seamen working aboard ships, either commercial or naval vessels, as compared to that of the general population.
Methods: We carried out a literature search in MEDLINE through PubMed and EMBASE, from inception to 31 December 2021, of all studies on seamen working aboard ships, either commercial or naval vessels, characterized by exposure to asbestos and providing mesothelioma risk estimates. The Newcastle-Ottawa Scale was used to assess the quality of the studies included. The pooled standardized mortality ratio (SMR) was computed across eligible studies. The study protocol was registered on PROSPERO and reporting followed the preferred reporting items for systematic reviews and meta-analyses guidelines.
Results: A total of 10 studies published from 1990 to 2020 were considered eligible and included in the systematic review and meta-analysis. All the included studies were of good quality, with a median score of seven out of nine. Overall, there were 235 mesothelioma cases/deaths in the included studies versus 115.6 expected, with a pooled SMR of 2.11 (95% confidence intervals, 1.70-2.62), in the absence of a significant between-study heterogeneity ( I2 = 39%, P = 0.11).
Conclusion: A more than double excess risk for mesothelioma among seamen working aboard ships emerged from our meta-analysis.
{"title":"Mesothelioma among seamen: a systematic review and meta-analysis.","authors":"Matteo Rota, Angelo Viscardi, Francesca Maghin, Donatella Placidi, Adelaide Conti","doi":"10.1097/CEJ.0000000000000875","DOIUrl":"10.1097/CEJ.0000000000000875","url":null,"abstract":"<p><strong>Objectives: </strong>Navy personnel and seafarers live and work 24 h per day in the shipboard environment and they are exposed to asbestos fibers released into the confined spaces aboard ships. We conducted a systematic review and meta-analysis to quantify the mesothelioma risk of seamen working aboard ships, either commercial or naval vessels, as compared to that of the general population.</p><p><strong>Methods: </strong>We carried out a literature search in MEDLINE through PubMed and EMBASE, from inception to 31 December 2021, of all studies on seamen working aboard ships, either commercial or naval vessels, characterized by exposure to asbestos and providing mesothelioma risk estimates. The Newcastle-Ottawa Scale was used to assess the quality of the studies included. The pooled standardized mortality ratio (SMR) was computed across eligible studies. The study protocol was registered on PROSPERO and reporting followed the preferred reporting items for systematic reviews and meta-analyses guidelines.</p><p><strong>Results: </strong>A total of 10 studies published from 1990 to 2020 were considered eligible and included in the systematic review and meta-analysis. All the included studies were of good quality, with a median score of seven out of nine. Overall, there were 235 mesothelioma cases/deaths in the included studies versus 115.6 expected, with a pooled SMR of 2.11 (95% confidence intervals, 1.70-2.62), in the absence of a significant between-study heterogeneity ( I2 = 39%, P = 0.11).</p><p><strong>Conclusion: </strong>A more than double excess risk for mesothelioma among seamen working aboard ships emerged from our meta-analysis.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"438-447"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140179431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-02-20DOI: 10.1097/CEJ.0000000000000878
Soyeoun Kim, Thi Xuan Mai Tran, Mi Kyung Kim, Min Sung Chung, Eun Hye Lee, Woojoo Lee, Boyoung Park
Background: We investigated the association between established risk factors for breast cancer and mammographic breast density in Korean women.
Methods: This large cross-sectional study included 8 460 928 women aged >40 years, who were screened for breast cancer between 2009 and 2018. Breast density was assessed using the Breast Imaging Reporting and Data System. This study used multiple logistic regression analyses of age, BMI, age at menarche, menopausal status, menopausal age, parity, breastfeeding status, oral contraceptive use, family history of breast cancer, physical activity, smoking, drinking and hormone replacement therapy use to investigate their associations with mammographic breast density. Analyses were performed using SAS software.
Results: Of 8 460 928 women, 4 139 869 (48.9%) had nondense breasts and 4 321 059 (51.1%) had dense breasts. Factors associated with dense breasts were: earlier age at menarche [<15 vs. ≥15; adjusted odds ratio (aOR), 1.18; 95% confidence interval (CI), 1.17-1.18], premenopausal status (aOR, 2.01; 95% CI, 2.00-2.02), later age at menopause (≥52 vs. <52; aOR, 1.23; 95% CI, 1.22-1.23), nulliparity (aOR, 1.64; 95% CI, 1.63-1.65), never breastfed (aOR, 1.23; 95% CI, 1.23-1.24) and use of hormone replacement therapy (aOR, 1.29; 95% CI, 1.28-1.29). Women with a higher BMI and the use of oral contraceptives were more likely to have nondense breasts.
Conclusion: Lower BMI, reproductive health and behavioral factors were associated with dense breasts in Korean women. Additional research should investigate the relationship between mammographic breast density, breast cancer risk factors and breast cancer risk.
{"title":"Associations between breast cancer risk factors and mammographic breast density in a large cross-section of Korean women.","authors":"Soyeoun Kim, Thi Xuan Mai Tran, Mi Kyung Kim, Min Sung Chung, Eun Hye Lee, Woojoo Lee, Boyoung Park","doi":"10.1097/CEJ.0000000000000878","DOIUrl":"10.1097/CEJ.0000000000000878","url":null,"abstract":"<p><strong>Background: </strong>We investigated the association between established risk factors for breast cancer and mammographic breast density in Korean women.</p><p><strong>Methods: </strong>This large cross-sectional study included 8 460 928 women aged >40 years, who were screened for breast cancer between 2009 and 2018. Breast density was assessed using the Breast Imaging Reporting and Data System. This study used multiple logistic regression analyses of age, BMI, age at menarche, menopausal status, menopausal age, parity, breastfeeding status, oral contraceptive use, family history of breast cancer, physical activity, smoking, drinking and hormone replacement therapy use to investigate their associations with mammographic breast density. Analyses were performed using SAS software.</p><p><strong>Results: </strong>Of 8 460 928 women, 4 139 869 (48.9%) had nondense breasts and 4 321 059 (51.1%) had dense breasts. Factors associated with dense breasts were: earlier age at menarche [<15 vs. ≥15; adjusted odds ratio (aOR), 1.18; 95% confidence interval (CI), 1.17-1.18], premenopausal status (aOR, 2.01; 95% CI, 2.00-2.02), later age at menopause (≥52 vs. <52; aOR, 1.23; 95% CI, 1.22-1.23), nulliparity (aOR, 1.64; 95% CI, 1.63-1.65), never breastfed (aOR, 1.23; 95% CI, 1.23-1.24) and use of hormone replacement therapy (aOR, 1.29; 95% CI, 1.28-1.29). Women with a higher BMI and the use of oral contraceptives were more likely to have nondense breasts.</p><p><strong>Conclusion: </strong>Lower BMI, reproductive health and behavioral factors were associated with dense breasts in Korean women. Additional research should investigate the relationship between mammographic breast density, breast cancer risk factors and breast cancer risk.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"407-413"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-02-20DOI: 10.1097/CEJ.0000000000000877
Yong Zhu
Objective: The incidence of neuroendocrine tumors (NET) has been increasing globally for several decades. The objective of the study was to examine the most recent trend in the incidence of NET as well as disparities by sex and race/ethnicity in adults in the USA.
Methods: Patients with NET aged ≥20 years were identified from the SEER 22 Registries from 2000 to 2020. The age-adjusted incidence rate was calculated for overall NET and by primary site. The incidence trend was assessed by annual percent change. Disparities by sex and race/ethnicity were examined using the incidence rate ratio.
Results: Age-adjusted incidence rate of overall NET in adults was 9.39 per 100 000 in 2000-2020. The incidence rate increased from 2000 but reached a plateau with no significant change since 2015. The lung and bronchus, small intestine, and rectum were the most common primary sites. Sex and racial/ethnic disparities in NET incidence varied by primary sites. For example, there was a female excess in NET of the lung and bronchus, stomach, and appendix; and there was a male excess in the small intestine, pancreas, colon, rectum and other/unknown NET. Compared to non-Hispanic white, non-Hispanic black had higher incidences of stomach, small intestine, liver, pancreas, colon, rectum, and other/unknown NET; they had lower incidences of lung and bronchus, and appendix NET than non-Hispanic white.
Conclusion: Age-adjusted incidence rate of overall NET has reached a plateau since 2015. However, there were sex and racial/ethnic disparities in such incidence, which varied depending on the primary site of NET.
{"title":"Incidence trend of neuroendocrine tumors and disparities by sex and race/ethnicity in adults from the United States, 2000-2020.","authors":"Yong Zhu","doi":"10.1097/CEJ.0000000000000877","DOIUrl":"10.1097/CEJ.0000000000000877","url":null,"abstract":"<p><strong>Objective: </strong>The incidence of neuroendocrine tumors (NET) has been increasing globally for several decades. The objective of the study was to examine the most recent trend in the incidence of NET as well as disparities by sex and race/ethnicity in adults in the USA.</p><p><strong>Methods: </strong>Patients with NET aged ≥20 years were identified from the SEER 22 Registries from 2000 to 2020. The age-adjusted incidence rate was calculated for overall NET and by primary site. The incidence trend was assessed by annual percent change. Disparities by sex and race/ethnicity were examined using the incidence rate ratio.</p><p><strong>Results: </strong>Age-adjusted incidence rate of overall NET in adults was 9.39 per 100 000 in 2000-2020. The incidence rate increased from 2000 but reached a plateau with no significant change since 2015. The lung and bronchus, small intestine, and rectum were the most common primary sites. Sex and racial/ethnic disparities in NET incidence varied by primary sites. For example, there was a female excess in NET of the lung and bronchus, stomach, and appendix; and there was a male excess in the small intestine, pancreas, colon, rectum and other/unknown NET. Compared to non-Hispanic white, non-Hispanic black had higher incidences of stomach, small intestine, liver, pancreas, colon, rectum, and other/unknown NET; they had lower incidences of lung and bronchus, and appendix NET than non-Hispanic white.</p><p><strong>Conclusion: </strong>Age-adjusted incidence rate of overall NET has reached a plateau since 2015. However, there were sex and racial/ethnic disparities in such incidence, which varied depending on the primary site of NET.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"475-484"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-03-06DOI: 10.1097/CEJ.0000000000000881
Cornelia Richter, Lea Wildisen, Sabine Rohrmann, Sarah R Haile
Objective: Various approaches have been used in the literature to handle missing vital status data in cancer registries. We aimed to compare these approaches to determine which led to the least biased estimates in typical analytic tasks of cancer registries.
Methods: A simulation study was performed using data from the Swiss National Agency for Cancer Registration for six tumor types. First, 5%, 10% and 15% missingness in the vital status were introduced artificially in the complete data. Second, missing vital status data were handled by applying no, single or multiple imputations. Five-year overall survival estimates, relative survival or standardized incidence ratio were computed. Estimates were compared with the true value.
Results: Standardized incidence ratio estimates for colorectal cancer obtained with multiple imputation yielded least biased results (-0.06 to -0.04), but the widest confidence intervals. Single imputation was more biased (-0.32) than using no imputation at all (-0.21). A similar pattern was observed for overall survival and relative survival.
Conclusion: This simulation study indicated that often used single imputation (sometimes referred to as simulating follow-up times) techniques to fill in missing vital status data are likely too biased to be useful in practice. Multiple imputation approaches yielded standardized incidence ratio, overall and relative survival estimates with the least bias, indicating reasonable performance that is likely to generalize to other settings.
{"title":"Better tools for better estimates: improving approaches to handling missing data in Swiss cancer registries.","authors":"Cornelia Richter, Lea Wildisen, Sabine Rohrmann, Sarah R Haile","doi":"10.1097/CEJ.0000000000000881","DOIUrl":"10.1097/CEJ.0000000000000881","url":null,"abstract":"<p><strong>Objective: </strong>Various approaches have been used in the literature to handle missing vital status data in cancer registries. We aimed to compare these approaches to determine which led to the least biased estimates in typical analytic tasks of cancer registries.</p><p><strong>Methods: </strong>A simulation study was performed using data from the Swiss National Agency for Cancer Registration for six tumor types. First, 5%, 10% and 15% missingness in the vital status were introduced artificially in the complete data. Second, missing vital status data were handled by applying no, single or multiple imputations. Five-year overall survival estimates, relative survival or standardized incidence ratio were computed. Estimates were compared with the true value.</p><p><strong>Results: </strong>Standardized incidence ratio estimates for colorectal cancer obtained with multiple imputation yielded least biased results (-0.06 to -0.04), but the widest confidence intervals. Single imputation was more biased (-0.32) than using no imputation at all (-0.21). A similar pattern was observed for overall survival and relative survival.</p><p><strong>Conclusion: </strong>This simulation study indicated that often used single imputation (sometimes referred to as simulating follow-up times) techniques to fill in missing vital status data are likely too biased to be useful in practice. Multiple imputation approaches yielded standardized incidence ratio, overall and relative survival estimates with the least bias, indicating reasonable performance that is likely to generalize to other settings.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"400-406"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The objective of this study is to evaluate the correlation between tumor proportionality scores (TPS) and the effectiveness of immune checkpoint inhibitors (ICIs) as the second or subsequent line therapies for individuals who received diagnoses of advanced non-small cell lung cancer (NSCLC).
Methods: The retrospective analysis was conducted on the medical records of a total of 143 patients who received diagnoses of stage IIIB/IV NSCLC and were admitted to our hospital from the beginning of 2019 to the end of September 2022. The follow-up period ended on 01 January 2023. The study used Kaplan-Meier survival curves to assess the progression-free survival (PFS) and overall survival (OS) of patients. Univariate and multivariate Cox proportional risk models were used to analyze the factors associated with the PFS and OS of advanced-stage NSCLC patients who received ICIs as the second or subsequent lines.
Results: Patients diagnosed with NSCLC who had a TPS ≥1% and got treatment with ICIs exhibit notably elevated rates of partial response, objective response rate, disease control rate and extended PFS in comparison to NSCLC patients with a TPS of <1% ( P < 0.05). NSCLC patients with TPS within 1-49% [hazard ratio (HR) = 0.372; 95% confidence interval (CI), 0.140-0.993; P = 0.048] or ≥50% (HR = 0.276; 95% CI, 0.095-0.796; P = 0.017) were significantly associated with prolonged PFS, which were conducted by multivariate Cox regression analysis.
Conclusion: Programmed death protein-1 expression status may be predictive markers of the effectiveness of ICIs as the second or subsequent lines of therapies in advanced NSCLC are influenced by TPS.
{"title":"Correlation between PD-L1 expression status and efficacy of immunotherapy as second-line or later-line therapy in advanced non-small cell lung cancer patients.","authors":"Jingya Liu, Yingchun Man, Jianing Gao, Xinxin Wang, Lijie Zhang, Mingheng Li, Jiahan Yu","doi":"10.1097/CEJ.0000000000000880","DOIUrl":"10.1097/CEJ.0000000000000880","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to evaluate the correlation between tumor proportionality scores (TPS) and the effectiveness of immune checkpoint inhibitors (ICIs) as the second or subsequent line therapies for individuals who received diagnoses of advanced non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>The retrospective analysis was conducted on the medical records of a total of 143 patients who received diagnoses of stage IIIB/IV NSCLC and were admitted to our hospital from the beginning of 2019 to the end of September 2022. The follow-up period ended on 01 January 2023. The study used Kaplan-Meier survival curves to assess the progression-free survival (PFS) and overall survival (OS) of patients. Univariate and multivariate Cox proportional risk models were used to analyze the factors associated with the PFS and OS of advanced-stage NSCLC patients who received ICIs as the second or subsequent lines.</p><p><strong>Results: </strong>Patients diagnosed with NSCLC who had a TPS ≥1% and got treatment with ICIs exhibit notably elevated rates of partial response, objective response rate, disease control rate and extended PFS in comparison to NSCLC patients with a TPS of <1% ( P < 0.05). NSCLC patients with TPS within 1-49% [hazard ratio (HR) = 0.372; 95% confidence interval (CI), 0.140-0.993; P = 0.048] or ≥50% (HR = 0.276; 95% CI, 0.095-0.796; P = 0.017) were significantly associated with prolonged PFS, which were conducted by multivariate Cox regression analysis.</p><p><strong>Conclusion: </strong>Programmed death protein-1 expression status may be predictive markers of the effectiveness of ICIs as the second or subsequent lines of therapies in advanced NSCLC are influenced by TPS.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"448-460"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-01-23DOI: 10.1097/CEJ.0000000000000871
Junwei Sun, Mingyu Wang, Zhisheng Kan
Background: We aimed to develop tools that could predict the occurrence of distant metastases in melanoma and its prognosis based on clinical and pathological characteristics.
Materials and methods: We obtained data from the Surveillance, Epidemiology, and End Results (SEER) database of melanoma patients diagnosed between 2010 and 2019. Logistic analyses were performed to identify independent risk factors associated with distant metastasis. Additionally, multivariate Cox analyses were conducted to determine independent prognostic factors for patients with distant metastasis. Two nomograms were established and evaluated with the receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Furthermore, we performed a retrospective analysis of melanoma with distant metastasis from our institute between March 2018 and June 2022.
Results: Of the total 19 396 melanoma patients, 352 (1.8%) had distant metastases at the time of diagnosis. The following clinical and pathological characteristics were identified as independent risk factors for distant metastasis in melanoma: N stage, tumor size, ulceration, mitosis, primary tumor site, and pathological subtype. Furthermore, tumor size, pathological subtype, and radiotherapy were identified as independent prognostic factors. The results of the training and validation cohorts' ROC curves, calibration, DCA, and Kaplan-Meier survival curves demonstrate the effectiveness of the two nomograms. The retrospective study results from our center supported the results from the SEER database.
Conclusion: The clinical and pathological characteristics of melanoma can predict a patient's risk of metastasis and prognosis, and the two nomograms are expected to be effective tools to guide therapy decisions.
{"title":"Diagnostic and prognostic risk factors analysis for distant metastasis in melanoma: a population-based study.","authors":"Junwei Sun, Mingyu Wang, Zhisheng Kan","doi":"10.1097/CEJ.0000000000000871","DOIUrl":"10.1097/CEJ.0000000000000871","url":null,"abstract":"<p><strong>Background: </strong>We aimed to develop tools that could predict the occurrence of distant metastases in melanoma and its prognosis based on clinical and pathological characteristics.</p><p><strong>Materials and methods: </strong>We obtained data from the Surveillance, Epidemiology, and End Results (SEER) database of melanoma patients diagnosed between 2010 and 2019. Logistic analyses were performed to identify independent risk factors associated with distant metastasis. Additionally, multivariate Cox analyses were conducted to determine independent prognostic factors for patients with distant metastasis. Two nomograms were established and evaluated with the receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Furthermore, we performed a retrospective analysis of melanoma with distant metastasis from our institute between March 2018 and June 2022.</p><p><strong>Results: </strong>Of the total 19 396 melanoma patients, 352 (1.8%) had distant metastases at the time of diagnosis. The following clinical and pathological characteristics were identified as independent risk factors for distant metastasis in melanoma: N stage, tumor size, ulceration, mitosis, primary tumor site, and pathological subtype. Furthermore, tumor size, pathological subtype, and radiotherapy were identified as independent prognostic factors. The results of the training and validation cohorts' ROC curves, calibration, DCA, and Kaplan-Meier survival curves demonstrate the effectiveness of the two nomograms. The retrospective study results from our center supported the results from the SEER database.</p><p><strong>Conclusion: </strong>The clinical and pathological characteristics of melanoma can predict a patient's risk of metastasis and prognosis, and the two nomograms are expected to be effective tools to guide therapy decisions.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"461-474"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-02-20DOI: 10.1097/CEJ.0000000000000879
Jeanne M Ward, Frances Hardin-Fanning
Objective: The objective of this study was toidentify and appraise available sun protection self-efficacy instruments and synthesize information.
Data source: A systematic search of electronic databases from 2005 to 2023 included PubMed, CINAHL, Embase and PsycINFO .
Background: While instruments have been developed to evaluate sun-protective behaviors and self-efficacy separately, sun-protection self-efficacy instruments have yet to be widely studied. Self-efficacy is an essential antecedent to performing health-related behaviors or practices that can promote or hinder the health of individuals and groups.
Study inclusion and exclusion criteria: Studies randomized control trials or descriptive studies that used self-efficacy measurement tools to evaluate behaviors, intentions, and sun protection knowledge were included in this review. Sun protection surveys that targeted providers or parents and non-English articles were excluded.
Data extraction: Data were extracted by one independent researcher.
Data synthesis: Fifteen studies met the inclusion criterion and included 10 scales of self-efficacy in sun protection. Study design and purpose, and the instrument's validity and reliability statistics, including Cronbach's alphas, were extracted.
Results: The two-factor self-efficacy in sun protection scale was the most common measure for primary prevention, with acceptable reliability and validity. However, other instruments also showed reliable psychometric properties, especially measures of sunscreen self-efficacy.
Conclusion: More research in self-efficacy measurement is warranted to examine specific populations and determine the appropriate constructs of self-efficacy. It is crucial to design evidence-based interventions that affect self-efficacy, are measured by a reliable, valid instrument, and have the potential to increase sun-protective and screening behaviors.
{"title":"Systematic review and analysis of self-efficacy in sun protection measurement instruments.","authors":"Jeanne M Ward, Frances Hardin-Fanning","doi":"10.1097/CEJ.0000000000000879","DOIUrl":"10.1097/CEJ.0000000000000879","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was toidentify and appraise available sun protection self-efficacy instruments and synthesize information.</p><p><strong>Data source: </strong>A systematic search of electronic databases from 2005 to 2023 included PubMed, CINAHL, Embase and PsycINFO .</p><p><strong>Background: </strong>While instruments have been developed to evaluate sun-protective behaviors and self-efficacy separately, sun-protection self-efficacy instruments have yet to be widely studied. Self-efficacy is an essential antecedent to performing health-related behaviors or practices that can promote or hinder the health of individuals and groups.</p><p><strong>Study inclusion and exclusion criteria: </strong>Studies randomized control trials or descriptive studies that used self-efficacy measurement tools to evaluate behaviors, intentions, and sun protection knowledge were included in this review. Sun protection surveys that targeted providers or parents and non-English articles were excluded.</p><p><strong>Data extraction: </strong>Data were extracted by one independent researcher.</p><p><strong>Data synthesis: </strong>Fifteen studies met the inclusion criterion and included 10 scales of self-efficacy in sun protection. Study design and purpose, and the instrument's validity and reliability statistics, including Cronbach's alphas, were extracted.</p><p><strong>Results: </strong>The two-factor self-efficacy in sun protection scale was the most common measure for primary prevention, with acceptable reliability and validity. However, other instruments also showed reliable psychometric properties, especially measures of sunscreen self-efficacy.</p><p><strong>Conclusion: </strong>More research in self-efficacy measurement is warranted to examine specific populations and determine the appropriate constructs of self-efficacy. It is crucial to design evidence-based interventions that affect self-efficacy, are measured by a reliable, valid instrument, and have the potential to increase sun-protective and screening behaviors.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"390-399"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}